WASHINGTON (AP) -- Gilead Science Inc.'s earnings tumbled more than 17 percent in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales....
By MATTHEW PERRONE, Associated Press: Business
Thu, 04/28/2016 - 3:04pm
WASHINGTON (AP) -- Gilead Science Inc.'s earnings tumbled more than 17 percent in the first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales....